← Back to Search

Polyphenol

Curcumin for Renal Transplant Health

N/A

Waitlist Available

Led By Pierpaolo Di Cocco, MD, PhD

Research Sponsored by University of Illinois at Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

The subject is a recipient of a living donor or deceased donor kidney only transplant

The subject is > 18 years of age

Must not have

The subject has had a multi-organ transplant

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Summary

This trial will investigate whether curcumin can improve vascular function and cognitive impairment in kidney transplant recipients.

Who is the study for?

This trial is for adults over 18 who have received a kidney transplant from either a living or deceased donor. It's not open to those who've had multiple organ transplants or were taking curcumin before their kidney transplant.

What is being tested?

The study is testing if curcumin can help improve blood vessel function and brain health in people who have had a kidney transplant, comparing it with a placebo (a substance with no therapeutic effect).

What are the potential side effects?

While the document doesn't specify side effects, generally, curcumin may cause digestive upset, headache, rash and yellow stool; however, most people tolerate it well.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have received a kidney transplant from a living or deceased donor.

Select...

I am older than 18 years.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had a transplant involving multiple organs.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Cognitive function & Pain

Graft Outcomes

Inflammation and oxidative stress

Side effects data

From 2023 Phase 4 trial • 58 Patients • NCT04205929

Migraine headache

Stomach cramps

100%

80%

60%

40%

20%

Study treatment Arm

Placebo Group

Curcumin Group

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Curcumin Arm (Arm 1)Experimental Treatment1 Intervention

20 subjects will be randomized (1:1) to this arm and receive curcumin for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood samples and questionnaires.

Group II: Placebo Arm (Arm 2)Placebo Group1 Intervention

20 subjects will be randomized (1:1) to this arm and receive placebo for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood samples and questionnaires.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Curcumin

2017

Completed Phase 4

~1070

0 / 3Eligibility criteria met